MDRX

Veradigm Inc. (MDRX) | Rumor.io

Veradigm

MDRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio11

Market capitalization550.4M

Earnings per share-2.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 10

Veradigm Inc. ($MDRX) has updated its FY 2023 guidance to $608-622M in revenue and 0.790-0.880 EPS, below consensus.
Veradigm Inc. shares have fallen 12-13% after the company lowered its FY 2023 revenue guidance.
The new CEO of Veradigm Inc. has provided a confident outlook on the company's business and strategy, despite current headwinds.

Generated by AI

Sentiment

Of the messages about MDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% +22.01
Bearish	—	—	—	5.26% -22.01

Bullish· Oct 14

Veradigm Inc. (MDRX) shares jumped 30% after announcing the sale of its CarePort Health business to WellSky for $1.35 billion.
The sale of CarePort at a premium price is a positive sign for the company's future prospects, with some traders expecting the stock to reach $12 or higher.
The sale of CarePort has already led to a significant increase in MDRX premiums, making it an attractive play for traders looking to capitalize on the stock's momentum.

Bearish· Oct 14

$MDRX's recent performance has been poor, with a large gap down to fill and a history of selling off business units, including a $200 million loss last year.
The company's decision to sell off business units has raised concerns about its future prospects, with some investors questioning the logic behind this strategy.
$MDRX's stock has been stair-stepping down since pre-market, with many uncertainties surrounding the company's performance, and a lack of buying interest compared to selling.

Generated by AI

Topics

Of the messages about MDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.78%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	22.22%

Earnings· Nov 1

Veradigm Inc. ($MDRX) reported Q3 earnings of 18c EPS and $535.80M in revenue.
$MDRX missed the Estimize EPS consensus by 1c and the revenue consensus by $12.16M.
$MDRX's earnings of 18c EPS were lower than the estimated 20c EPS, but met the Earnings Whisper estimate of 21c.

Analysts· Nov 2

Analysts at Cantor Fitzgerald cut Veradigm Inc. (MDRX) to Neutral from Overweight.
Several analysts, including JPMorgan Chase and SunTrust, downgraded Veradigm Inc. (MDRX) to Neutral or Hold.
Robert W. Baird and Citigroup lowered their price targets for Veradigm Inc. (MDRX) to $14.00 and $17.00, respectively.

Announcements· Jan 11

Veradigm Inc. (MDRX) announces a new $250 million share repurchase program, replacing a prior authorization of the same amount.
The company expects revenue to be between $640 million and $660 million in Fiscal 2023.
Veradigm also provides initial financial guidance for Fiscal 2023, expecting EPS to be above consensus.

Technical Analysis· Nov 2

$MDRX price is above its 200-day simple moving average (SMA), indicating a potential uptrend.
The stock's price action is closely watched by traders, with some monitoring its movement against key technical levels.
The 200-day SMA serves as a key indicator for long-term trend direction in the Veradigm Inc. stock.

Generated by AI

Community

Of the messages about MDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	42.86%
Newcomers	—	—	—	57.14%

Regulars· Jan 11

Veradigm Inc. ($MDRX) announces a new $250 million share repurchase program, replacing a prior authorization, and initiates fiscal 2023 guidance.
The company's Aroon indicator has dropped into a downtrend, according to the latest market data.
Veradigm's FY23 EPS is expected to be above consensus, with FY23 revenue in line, according to the company's latest guidance.

Newcomers· Jan 26

Newcomers are watching $MDRX for its potential to break out of a stage 1 base, driven by a 477% daily volume surge.
The stock is trading at 52-week highs and expanding its volume, suggesting good strength according to Mansfield RS.
$MDRX is being discussed for its recent 16% price increase, with various news sources attributing the gain to unspecified factors.

Generated by AI

375-Page Report Ranks Competitors Across the Company Evaluation Matrix as Asia Pacific Emerges as the Fastest-Growing Region on Digital Health Expansion Care Management Solutions Market Care Management Solutions Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Care Management Solutions Market by Component, Application, Deployment, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global care management solutions market is projected to grow from US

21d agoYahoo! Finance Canada

Veradigm Announces Updated Presentation Time for Upcoming Investor Conference

CHICAGO, September 08, 2026--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that it will now present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15th at 3:35PM CT. A live webcast of the fireside chat will be available at the Veradigm investor relations website.

22d agoYahoo Finance Australia

Did Veradigm Inc. Insiders Breach their Fiduciary Duties to Shareholders?

27d agoMorningstar

Veradigm to Participate in Two Upcoming Investor Conferences

CHICAGO, August 17, 2026--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management will be participating in the following investor conferences in September.

1mo agoYahoo Finance

Also Discussed

Investors talking about MDRX also mention

#	Name	Attention
1	Nu Skin Enterprises Inc.NUS	0%0
2	Veeva Systems Inc.VEEV	0%0
3	MGIC Investment Corp.MTG	0%0
4	Illumina Inc.ILMN	0%+0
5	McKesson CorporationMCK	0%0
6	ICON plcICLR	0%0
7	Computer Programs & Systems IncCPSI	0%0
8	Evolent Health IncEVH	0%0
9	Pediatrix Medical Group, Inc.MD	0%0
10	American Well Corporation Class A Common StockAMWL	0%+0

Veradigm Inc.

Healthcare
Health Information Services

Veradigm Inc. is a healthcare technology company specializing in data-driven solutions that connect providers, payers, and life science organizations. The company’s core offerings include electronic health records (EHR), practice management software, and analytics tools designed to optimize clinical, financial, and operational outcomes. It serves over 180,000 physicians and supports 2,700 hospitals through platforms that enhance care coordination, patient engagement, and population health management. Veradigm leverages its extensive healthcare data network to deliver actionable insights for clinical research, revenue cycle management, and value-based care initiatives. Historically known as Allscripts, the company rebranded in 2023 to reflect its focus on scalable, AI-enhanced solutions. Despite recent regulatory challenges, including a 2024 Nasdaq suspension for delayed financial filings, Veradigm remains a significant player in healthcare IT, bridging gaps across the ecosystem through interoperable technology and data interoperability standards.

Website

Location

222 Merchandise Mart Plaza

Chicago, IL, 60654

United States

Social

What share of all stock conversation is about MDRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 10

Veradigm Inc. ($MDRX) has updated its FY 2023 guidance to $608-622M in revenue and 0.790-0.880 EPS, below consensus.
Veradigm Inc. shares have fallen 12-13% after the company lowered its FY 2023 revenue guidance.
The new CEO of Veradigm Inc. has provided a confident outlook on the company's business and strategy, despite current headwinds.

Generated by AI

Sentiment

Of the messages about MDRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	94.74% +22.01
Bearish	—	—	—	5.26% -22.01

Bullish· Oct 14

Veradigm Inc. (MDRX) shares jumped 30% after announcing the sale of its CarePort Health business to WellSky for $1.35 billion.
The sale of CarePort at a premium price is a positive sign for the company's future prospects, with some traders expecting the stock to reach $12 or higher.
The sale of CarePort has already led to a significant increase in MDRX premiums, making it an attractive play for traders looking to capitalize on the stock's momentum.

Bearish· Oct 14

$MDRX's recent performance has been poor, with a large gap down to fill and a history of selling off business units, including a $200 million loss last year.
The company's decision to sell off business units has raised concerns about its future prospects, with some investors questioning the logic behind this strategy.
$MDRX's stock has been stair-stepping down since pre-market, with many uncertainties surrounding the company's performance, and a lack of buying interest compared to selling.

Generated by AI

Topics

Of the messages about MDRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.78%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	22.22%

Earnings· Nov 1

Veradigm Inc. ($MDRX) reported Q3 earnings of 18c EPS and $535.80M in revenue.
$MDRX missed the Estimize EPS consensus by 1c and the revenue consensus by $12.16M.
$MDRX's earnings of 18c EPS were lower than the estimated 20c EPS, but met the Earnings Whisper estimate of 21c.

Analysts· Nov 2

Analysts at Cantor Fitzgerald cut Veradigm Inc. (MDRX) to Neutral from Overweight.
Several analysts, including JPMorgan Chase and SunTrust, downgraded Veradigm Inc. (MDRX) to Neutral or Hold.
Robert W. Baird and Citigroup lowered their price targets for Veradigm Inc. (MDRX) to $14.00 and $17.00, respectively.

Announcements· Jan 11

Veradigm Inc. (MDRX) announces a new $250 million share repurchase program, replacing a prior authorization of the same amount.
The company expects revenue to be between $640 million and $660 million in Fiscal 2023.
Veradigm also provides initial financial guidance for Fiscal 2023, expecting EPS to be above consensus.

Technical Analysis· Nov 2

$MDRX price is above its 200-day simple moving average (SMA), indicating a potential uptrend.
The stock's price action is closely watched by traders, with some monitoring its movement against key technical levels.
The 200-day SMA serves as a key indicator for long-term trend direction in the Veradigm Inc. stock.

Generated by AI

Community

Of the messages about MDRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	42.86%
Newcomers	—	—	—	57.14%

Regulars· Jan 11

Veradigm Inc. ($MDRX) announces a new $250 million share repurchase program, replacing a prior authorization, and initiates fiscal 2023 guidance.
The company's Aroon indicator has dropped into a downtrend, according to the latest market data.
Veradigm's FY23 EPS is expected to be above consensus, with FY23 revenue in line, according to the company's latest guidance.

Newcomers· Jan 26

Newcomers are watching $MDRX for its potential to break out of a stage 1 base, driven by a 477% daily volume surge.
The stock is trading at 52-week highs and expanding its volume, suggesting good strength according to Mansfield RS.
$MDRX is being discussed for its recent 16% price increase, with various news sources attributing the gain to unspecified factors.

Generated by AI

Veradigm

Social

Jan 10

Bullish· Oct 14

Bearish· Oct 14

Earnings· Nov 1

Analysts· Nov 2

Announcements· Jan 11

Technical Analysis· Nov 2

Regulars· Jan 11

Newcomers· Jan 26

Care Management Solutions Market Report Now Available — Forecasts Market Growth from $22.56B (2026) to $42.62B by 2031, Profiling Optum, Epic Systems, Oracle, Philips, Veradigm, and 20 Other Key Players

Veradigm Announces Updated Presentation Time for Upcoming Investor Conference

Did Veradigm Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Veradigm to Participate in Two Upcoming Investor Conferences

Also Discussed

Veradigm Inc.

Company Information

Location

Care Management Solutions Market Report Now Available — Forecasts Market Growth from $22.56B (2026) to $42.62B by 2031, Profiling Optum, Epic Systems, Oracle, Philips, Veradigm, and 20 Other Key Players

Veradigm Announces Updated Presentation Time for Upcoming Investor Conference

Did Veradigm Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Veradigm to Participate in Two Upcoming Investor Conferences

Also Discussed

Social

Jan 10

Bullish· Oct 14

Bearish· Oct 14

Earnings· Nov 1

Analysts· Nov 2

Announcements· Jan 11

Technical Analysis· Nov 2

Regulars· Jan 11

Newcomers· Jan 26